Insights

Expanding Product Range Diasorin Molecular's recent launch of new diagnostic kits such as the Simplexa C. auris Direct and Legionella Urinary Antigen Assay presents opportunities to target laboratories and healthcare providers seeking innovative solutions for emerging infectious diseases and antibiotic-resistant pathogens.

Geographic Growth The company's expansion into China with a new facility in Shanghai and its ongoing global distribution network indicate potential sales avenues in rapidly developing markets that are increasing investments in molecular diagnostics.

Market Penetration With a diverse portfolio including targeted and syndromic testing systems like Simplexa and VERIGENE, there are opportunities to engage hospitals and reference labs looking to streamline workflow and enhance diagnostic accuracy.

Strategic Acquisitions The acquisition of Luminex and related assets enhances Diasorin's technological capabilities and product portfolio, creating cross-selling opportunities and expanding reach into complex diagnostics and immunoassays.

Industry Alignment Working within regulated environments such as ISO 13485 and with leading healthtech partnerships, there are sales prospects for hospitals and labs seeking compliant, certified diagnostic solutions aligned with stringent industry standards.

Diasorin - Molecular Tech Stack

Diasorin - Molecular uses 8 technology products and services including ISO 13485, Salesforce CPQ, Modernizr, and more. Explore Diasorin - Molecular's tech stack below.

  • ISO 13485
    Certificates
  • Salesforce CPQ
    Configure Price Quote
  • Modernizr
    Javascript Libraries
  • Dun & Bradstreet
    Marketing Data Providers
  • PHP
    Programming Languages
  • Linux
    Programming Languages
  • Apache Subversion
    Source Code Management
  • SAP Concur
    Travel And Expense Management

Media & News

Diasorin - Molecular's Email Address Formats

Diasorin - Molecular uses at least 1 format(s):
Diasorin - Molecular Email FormatsExamplePercentage
First.Last@diasorin.comJohn.Doe@diasorin.com
95%
FirstLast@diasorin.comJohnDoe@diasorin.com
3%
First.MiddleLast@diasorin.comJohn.MichaelDoe@diasorin.com
1%
First@diasorin.comJohn@diasorin.com
1%

Frequently Asked Questions

Where is Diasorin - Molecular's headquarters located?

Minus sign iconPlus sign icon
Diasorin - Molecular's main headquarters is located at 12212 Technology Boulevard, Suite 130. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Diasorin - Molecular's official website and social media links?

Minus sign iconPlus sign icon
Diasorin - Molecular's official website is diasorin.com and has social profiles on LinkedIn.

What is Diasorin - Molecular's SIC code NAICS code?

Minus sign iconPlus sign icon
Diasorin - Molecular's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Diasorin - Molecular have currently?

Minus sign iconPlus sign icon
As of December 2025, Diasorin - Molecular has approximately 1K employees across 4 continents, including North AmericaAsiaEurope. Key team members include President: J. H.Owner And Photographer: L. H.Owner Of Corporate Tax Advisors: R. L.. Explore Diasorin - Molecular's employee directory with LeadIQ.

What industry does Diasorin - Molecular belong to?

Minus sign iconPlus sign icon
Diasorin - Molecular operates in the Biotechnology Research industry.

What technology does Diasorin - Molecular use?

Minus sign iconPlus sign icon
Diasorin - Molecular's tech stack includes ISO 13485Salesforce CPQModernizrDun & BradstreetPHPLinuxApache SubversionSAP Concur.

What is Diasorin - Molecular's email format?

Minus sign iconPlus sign icon
Diasorin - Molecular's email format typically follows the pattern of First.Last@diasorin.com. Find more Diasorin - Molecular email formats with LeadIQ.

When was Diasorin - Molecular founded?

Minus sign iconPlus sign icon
Diasorin - Molecular was founded in 1978.

Diasorin - Molecular

Biotechnology ResearchTexas, United States1001-5000 Employees

Diasorin’s molecular business, a combination of DiaSorin Molecular LLC and the Luminex Corporation Molecular products divisions, is now together as Diasorin. We specialize in the production of a comprehensive portfolio that includes targeted and syndromic molecular diagnostic products that are distributed globally to help laboratories streamline workflow and improve patient management.

Our Simplexa® Direct kits for targeted molecular testing include products for congenital CMV, HSV 1 & 2, Flu A/B & RSV, COVID-19, COVID-19 & Flu A/B, Bordetella, VZV, Group A Strep, GBS, and C. difficile. Simplexa® products are designed for use on the LIAISON® MDX, a real-time PCR instrument. The instrument has the capability of running either an 8-well or 96-well disc, providing an ideal platform to accommodate low to high-volume testing needs. 

Our VERIGENE® panels for syndromic molecular testing include kits for bloodstream, respiratory, and gastrointestinal infections. The VERIGENE® System is a sample-to-answer system that enables clinicians to rapidly identify pathogens responsible for some of the most complex infectious diseases. 

Additionally, our menu includes over 65 primer pairs for laboratory developed tests. We proudly serve as a trusted vendor and partner to hospitals and reference laboratories, offering comprehensive sales, service, and support solutions. Our mission is to ensure that the right tests are delivered to the right patients at the right time, underscoring our commitment to enhancing healthcare outcomes.

Section iconCompany Overview

Headquarters
12212 Technology Boulevard, Suite 130
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1978
Employees
1001-5000

Section iconFunding & Financials

  • $100M$250M

    Diasorin - Molecular's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $100M$250M

    Diasorin - Molecular's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.